(Q57563922)

English

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

article

In more languages

Statements

scholarly article

0 references

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes (English)

0 references

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Margaretha Persson

object named as

M. Persson

2

0 references

5

object named as

B. Ahrén

0 references

author name string

J. Farngren

1

0 references

A. Schweizer

3

0 references

J. E. Foley

4

0 references

publication date

17 March 2014

0 references

Diabetes, Obesity and Metabolism

0 references

16

0 references

9

0 references

812-818

0 references

Alpha cell function in health and disease: influence of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal n

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Hormonal counterregulation during severe hypoglycaemia under everyday conditions in patients with type 1 and insulin-treated type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Regulation of glucagon secretion by incretins

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Minireview: The role of the autonomic nervous system in mediating the glucagon response to hypoglycemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Vagal, cholinergic regulation of pancreatic polypeptide secretion

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12284

21 January 2018

Identifiers

10.1111/DOM.12284

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57563922&oldid=1514179111"